From: Engineering strategies for customizing extracellular vesicle uptake in a therapeutic context
Disease models | In vivo/in vitro | Administration route | Delivery (sustained release/injection) | Engineered/non-engineered | Methods for Enhancing EVs therapeutic effects | References |
---|---|---|---|---|---|---|
Chronic liver failure | In vivo | Systemic | Sustained release | Hydrogel-mediated | – | [62] |
Alzheimer’s disease | In vivo | Systemic | Injection | Targeted | Engineering the dendritic cells to express Lamp2b fused to the neuron-specific RVG peptide for delivering exogenous siRNA | [43] |
Breast cancer | In vitro | – | – | Engineered-targeted | HEK293T cells transduced by a lentiviral vector bearing-LAMP2b-DARPin G3 chimeric gene for siRNA delivering | [88] |
Parkinson’s disease | In vivo/ in vitro | Systemic | – | Engineered | Catalase loading into exosomes by different methods | [125] |
Cartilage damage | In vivo/in vitro | Local | Injection | – | – | [5] |
Osteoarthritis | In vivo | Local | Injection | Engineered | miR-140-5p-overexpressing in human synovial MSCs for the production of enriched EV | [4] |